Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection

Jereb, John A.; Goldberg, Stefan V.; Powell, Krista; Villarino, M. Elsa; LoBue, Philip
December 2011
MMWR: Morbidity & Mortality Weekly Report;12/9/2011, Vol. 60 Issue 48, p1650
The article provides recommendations from the U.S. Centers for Disease Control and Prevention (CDC) for utilizing a isoniazid (INH)-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. The regimen can be regarded for other categories of patients when it provides practical advantages. The use of INH monotherapy has depended on extending the findings from randomized clinical trials. Intense adverse effects should be reported to the U.S. Food and Drug Administration and CDC.


Related Articles

  • Interruptions in Supplies of Second-Line Antituberculosis Drugs-- United States, 2005-2012. Seaworth, Barbara J.; Field, Kim; Flood, Jennifer; Saliba, Jouhayna; Mase, Sundari R.; Cronin, Ann; Shah, Neha; Jereb, John; Chorba, Terence // JAMA: Journal of the American Medical Association;3/6/2013, Vol. 309 Issue 9, p866 

    The article focuses on the growing issue of tuberculosis (TB) drug shortages in the U.S. It mentions the findings of the survey of TB control programs that was conducted by the National Tuberculosis Controllers Association (NTCA) which indicated that 79 percent of the responding health...

  • TB cluster centered on air traveler.  // Modern Medicine;Jun96, Vol. 64 Issue 6, p25 

    Reports that the Centers for Disease Control and Prevention is investigating whether an infected Korean woman could have spread Mycobacterium tuberculosis to other air travelers during four flights in the United States. Tests which revealed the presence of Mycobacterium tuberculosis in...

  • CDC Recommends New Treatment Regimen for Latent Mycobacterium Tuberculosis Infection. Lambert, Mara // American Family Physician;8/15/2012, Vol. 86 Issue 4, p373 

    The article focuses on the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on the treatment of latent Mycobacterium tuberculosis infection. Isoniazid and rifapentine are the key components of the new treatment regimen. Daily isoniazid therapy for a nine-month...

  • Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis - Colorado, 2011-2012.  // MMWR Recommendations & Reports;10/4/2013, Vol. 62 Issue 39, p805 

    The article discusses the transmission of Mycobacterium tuberculosis among high school students in Colorado from 2011 to 2012 with information on its clinical diagnosis and treatment using isoniazid and rifapentine. Topics include index patient, contact investigations, and resource capacity,...

  • Recombinant Trivalent Influenza Vaccine (Flublok): A Review of Its Use in the Prevention of Seasonal Influenza in Adults. Yang, Lily // Drugs;2013, Vol. 73 Issue 12, p1357 

    Flublok is a trivalent influenza vaccine manufactured using the baculovirus-insect cell system, which has a number of differences compared with the traditional embryonated chicken egg system. Flublok is the first vaccine containing recombinant protein to be approved for the prevention of...

  • Manufacturers argue against mandatory training for opioid prescribers. Traynor, Kate // American Journal of Health-System Pharmacy;1/15/2010, Vol. 67 Issue 2, p96 

    The article reports that manufacturers of opioid medications have requested U.S. Food and Drug Administration (FDA) to adopt a careful method for changing prescription practices as the agency develops a risk evaluation and mitigation strategy (REMS) for some of these medications. According to...

  • Cessation shelf is smokin'.  // Drug Store News;1/10/2011, Vol. 33 Issue 1, p46 

    The article reports on the programs initiated by the U.S. Centers for Disease Control and Prevention and the Food and Drug Administration.

  • Handwashing Versus Alcohol-Based Gels---FDA Information.  // Journal of Environmental Health;Sep2003, Vol. 66 Issue 2, p40 

    The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are working together to control the transmission of pathogens that can result in foodborne illnesses. Transmission of pathogenic bacteria, viruses, and parasites from raw food or from ill workers...

  • FDA, CDC award jobs worth up to $540m. Dickson, Virgil // PRWeek (U.S. Edition);Nov2012, Vol. 15 Issue 11, p7 

    The article discusses the Food and Drug Administration of the U.S. and the U.S. Centers for Disease Control and Prevention that has received 540 million dollars as a multi-year anti-smoking marketing contract.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics